Our top pick for
Apyx Medical Corporation is a medical devices business based in the US. Apyx Medical Corporation shares (APYX) are listed on the NASDAQ and all prices are listed in US Dollars. Apyx Medical Corporation employs 266 staff and has a trailing 12-month revenue of around USD$24.6 million.
|52-week range||USD$2.805 - USD$11.05|
|50-day moving average||USD$9.5656|
|200-day moving average||USD$6.8682|
|Wall St. target price||USD$12.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.678|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Apyx Medical Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Apyx Medical Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Apyx Medical Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Apyx Medical Corporation shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$24.6 million|
|Gross profit TTM||USD$19.1 million|
|Return on assets TTM||-18.47%|
|Return on equity TTM||-22.41%|
|Market capitalisation||USD$357.1 million|
TTM: trailing 12 months
There are currently 542,033 Apyx Medical Corporation shares held short by investors – that's known as Apyx Medical Corporation's "short interest". This figure is 4.3% up from 519,867 last month.
There are a few different ways that this level of interest in shorting Apyx Medical Corporation shares can be evaluated.
Apyx Medical Corporation's "short interest ratio" (SIR) is the quantity of Apyx Medical Corporation shares currently shorted divided by the average quantity of Apyx Medical Corporation shares traded daily (recently around 109723.27935223). Apyx Medical Corporation's SIR currently stands at 4.94. In other words for every 100,000 Apyx Medical Corporation shares traded daily on the market, roughly 4940 shares are currently held short.
However Apyx Medical Corporation's short interest can also be evaluated against the total number of Apyx Medical Corporation shares, or, against the total number of tradable Apyx Medical Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Apyx Medical Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Apyx Medical Corporation shares in existence, roughly 20 shares are currently held short) or 0.0163% of the tradable shares (for every 100,000 tradable Apyx Medical Corporation shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Apyx Medical Corporation.
Find out more about how you can short Apyx Medical Corporation stock.
We're not expecting Apyx Medical Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Apyx Medical Corporation's shares have ranged in value from as little as $2.805 up to $11.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apyx Medical Corporation's is 0.667. This would suggest that Apyx Medical Corporation's shares are less volatile than average (for this exchange).
Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the J-Plasma system allows surgeons to operate in eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.